TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2114722

Group type: EXPERIMENTAL
Intervention: Adjuvant portal infusion of 5‐fluorouracil in combination with mitomycin C
Number of subjects: 469

Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (strict adherence)
Number of subjects: 469

Group type: COMPARATOR
Intervention: No or incomplete chemotherapy
Number of subjects: 469
Study: 356601

Group type: EXPERIMENTAL
Intervention: Ritodrine (N = 14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (N = 15)
Number of subjects: 29
Study: 31202086

Group type: EXPERIMENTAL
Intervention: Certain condition (high-calorie meal with nutritional information)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Uncertain condition (meal alone)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both conditions (certain and uncertain)
Number of subjects: 85
Study: 28381814

Group type: EXPERIMENTAL
Intervention: Integrated care intervention and participatory workplace intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 150
Study: 26037513

Group type: EXPERIMENTAL
Intervention: 20 g intrinsically L-[1-(13)C]phenylalanine-labeled protein ingestion
Number of subjects: 23
Study: 24050416

Group type: EXPERIMENTAL
Intervention: COPE (Creating Opportunities for Personal Empowerment) Healthy Lifestyles TEEN Program
Number of subjects: 779
Study: 21945768

Group type: EXPERIMENTAL
Intervention: Chemomechanical method with Carisolv(TM) system
Number of subjects: 192

Group type: COMPARATOR
Intervention: Traditional mechanical method
Number of subjects: 192
Study: 19912735

Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Gengnianan Tablet (control)
Number of subjects: 96
Study: 17215115

Group type: EXPERIMENTAL
Intervention: Budesonide 64 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide 64 microg + Formoterol 9 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14674971

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg(‐1) followed by remifentanil 1 microg kg(‐1) (group PR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remifentanil 1 microg kg(‐1) followed by propofol 2.5 mg kg(‐1) (group RP)
Number of subjects: 30
Study: 11739068

Group type: EXPERIMENTAL
Intervention: Continuation treatment with nortriptyline-plus-perphenazine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Continuation treatment with nortriptyline-plus-placebo
Number of subjects: 29
Study: 9770818

Group type: EXPERIMENTAL
Intervention: Propofol without narcotic analgesics
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol combined with pyritramide (0.4 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bolus injection of propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bolus injection of thiopental
Number of subjects: 30
Study: 9357148

Group type: EXPERIMENTAL
Intervention: Low dose choline (500 mg TDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose choline (1000 mg TDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sorbitol)
Number of subjects: 0
Study: 2682004

Group type: EXPERIMENTAL
Intervention: Meciadanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasogastric aspiration
Number of subjects: 0
Study: 170634

Group type: EXPERIMENTAL
Intervention: Sodium fluoride high Beta‐phase calcium pyrophosphate dentifrice (1000 ppm fluoride)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Calcium pyrophosphate dentifrice without sodium fluoride (control)
Number of subjects: 567
Study: 31177717

Group type: EXPERIMENTAL
Intervention: Index method
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Comprehensive method
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ratio method
Number of subjects: 2
Study: 29310326

Group type: EXPERIMENTAL
Intervention: remifentanil (infused at 2 μg/kg/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: dexmedetomidine (infused at 0.4 μg/kg/h)
Number of subjects: 50
Study: 26663645

Group type: EXPERIMENTAL
Intervention: U-type TVT-Secur approach
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: H-type TVT-Secur approach
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both U-type and H-type TVT-Secur approaches
Number of subjects: 115
Study: 22135229

Group type: EXPERIMENTAL
Intervention: Early palliative care interventions directed at patient symptoms and caregiver support
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Not providing care for other dependents
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Caregiver's work situation
Number of subjects: 191
Study: 22107011

Group type: EXPERIMENTAL
Intervention: Referral to gynaecologist
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Referral to gynaecological oncologist
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Referral rates for ovarian cancer
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Referral rates for cervical cancer
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Referral rates for endometrial cancer
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Metropolitan vs Rural GPs
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Patient factors
Number of subjects: 1402
Study: 19632953

Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 16180017

Group type: EXPERIMENTAL
Intervention: Implementation of an evidence-based skin protection programme with a top-down and bottom-up strategy including management system and educational programme.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities of change agents as part of the intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Establishment of a formal management system alone.
Number of subjects: 0
Study: 15274171

Group type: EXPERIMENTAL
Intervention: EX/RP
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EX/RP+CMI
Number of subjects: 46

Group type: COMPARATOR
Intervention: CMI
Number of subjects: 46

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 46
Study: 11413351

Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg twice daily by Turbuhaler)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Salmeterol (100 microg twice daily by Diskhaler)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9430359

Group type: EXPERIMENTAL
Intervention: 3 million units (MU) rIFN‐alpha2b
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 million units (MU) rIFN‐alpha2b
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8427642

Group type: EXPERIMENTAL
Intervention: Thera‐Pulse (Kinetic Concepts)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Geo‐Matt (SpanAmerica)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Stage II ulcer patients
Number of subjects: 79
Study: 3025051

Group type: EXPERIMENTAL
Intervention: Dietary fiber
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28455162

Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Active treatment (sphincterotomy)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 103
Study: 28078544

Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip™ nasal endotracheal tube (ETT) with a posterior facing bevel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard nasal RAE endotracheal tube with a leftward facing bevel
Number of subjects: 60
Study: 26178282

Group type: EXPERIMENTAL
Intervention: Intraarticular etanercept injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual analog scale of pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functionality assessment
Number of subjects: 0
Study: 22952137

Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution (CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No solution (CON)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (WA)
Number of subjects: 10
Study: 21733322

Group type: EXPERIMENTAL
Intervention: PF-rich extract (500 mg daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: PF-rich extract (n 12)
Number of subjects: 34
Study: 19502035

Group type: EXPERIMENTAL
Intervention: Pre-warmed colloid followed by pre-warmed crystalloid solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-warmed infusion
Number of subjects: 30
Study: 16430793

Group type: EXPERIMENTAL
Intervention: Single injection (droperidol 2.5 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous group (droperidol 2.5 mg 2 day(‐1))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no droperidol)
Number of subjects: 120
Study: 12631529

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the basal ganglia (internal globus pallidum)
Number of subjects: 0
Study: 10883558

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) with breathing retraining (BR)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) without breathing retraining (BR)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 77
Study: 9166393

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg/day for 2 weeks, followed by 11 weeks of 500 mg/day elemental oral calcium)
Number of subjects: 24

Group type: COMPARATOR
Intervention: GnRH agonist alone (triptorelin 3.75 mg intramuscularly every 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Elemental calcium (500 mg/day continuously)
Number of subjects: 24
Study: 8222488

Group type: EXPERIMENTAL
Intervention: Prednicarbate 0.25%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrocortisone buteprate 0.1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocortisone 1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Drug-free vehicles
Number of subjects: 60
Study: 2988108

Group type: EXPERIMENTAL
Intervention: Guar gum (Guarem), 5 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fiber-enriched wheat bran (Fiberform), 10.5 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no fiber preparation)
Number of subjects: 0
Study: 29870556

Group type: EXPERIMENTAL
Intervention: Olesoxime (Group O)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combined Groups O and P
Number of subjects: 74
Study: 27155880

Group type: EXPERIMENTAL
Intervention: Work It Out Together DVD
Number of subjects: 170

Group type: COMPARATOR
Intervention: General Health Promotion DVD (HP)
Number of subjects: 170
Study: 24832191

Group type: EXPERIMENTAL
Intervention: BAl (4.8 g day(‐1) for 4 weeks, increased to 6.4 g day(‐1) for 2 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pl (CaCO3)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BAl and SB co-ingestion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pl‐SB
Number of subjects: 8
Study: 22877888

Group type: EXPERIMENTAL
Intervention: Interoceptive exposure (IE)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: CBT-based stress-management treatment (SM)
Number of subjects: 76
Study: 20977639

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mini-incision open donor nephrectomy (MIDN)
Number of subjects: 100
Study: 19023834

Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Number of subjects: 406

Group type: COMPARATOR
Intervention: Manual only
Number of subjects: 406
Study: 16087836

Group type: EXPERIMENTAL
Intervention: Custom prism spectacles incorporating bilateral prisms to match participants' preferred power and base direction
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Standard prism spectacles incorporating standard bilateral prisms (6 prism diopters base up for logMAR VA of 0.48-1.00 and 10 Delta base up for logMAR VA of 1.02-1.68)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo spectacles matched in weight and thickness to prism spectacles but without prism
Number of subjects: 225
Study: 12144195

Group type: EXPERIMENTAL
Intervention: Observational studies using quantitative, epidemiological methods (nonrandomized trials, cohort studies, case control methods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical database
Number of subjects: 0
Study: 10327079

Group type: EXPERIMENTAL
Intervention: Hemostagene
Number of subjects: 60

Group type: COMPARATOR
Intervention: Helistat
Number of subjects: 60
Study: 7866977

Group type: EXPERIMENTAL
Intervention: Benefits scale (summated Likert format)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Barriers scale (summated Likert format)
Number of subjects: 581
Study: 2017326

Group type: EXPERIMENTAL
Intervention: Moderate coagulation spots (average: 300 mW)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intense coagulation spots (average: 600 mW)
Number of subjects: 12
Study: 6886969

Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine as aqueous oral solution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine as intravenous infusion over 30 min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Caffeine elimination rate constant
Number of subjects: 16

Group type: COMPARATOR
Intervention: Apparent volume of distribution
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clearance of caffeine
Number of subjects: 16
Study: 30658460

Group type: EXPERIMENTAL
Intervention: Wheat albumin (WA) 1.5 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 28915861

Group type: EXPERIMENTAL
Intervention: PRODECIDE education program
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 216
Study: 26345338

Group type: EXPERIMENTAL
Intervention: Naltrexone therapy (4 weeks, oral administration)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (4 weeks, oral administration)
Number of subjects: 22
Study: 23974801

Group type: EXPERIMENTAL
Intervention: ART + Carisolv® gel
Number of subjects: 81

Group type: COMPARATOR
Intervention: ART (conventional ART technique)
Number of subjects: 81
Study: 22695473

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d) plus Twelve Step Facilitation (TSF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d) plus standard counseling
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo plus Twelve Step Facilitation (TSF)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo plus standard counseling
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 19282833

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 553
Study: 17580147

Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg by intravenous infusion 2 hours before operation)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (no induction therapy)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Daclizumab and Control
Number of subjects: 118
Study: 15837256

Group type: EXPERIMENTAL
Intervention: Primary aldosteronism (PA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Essential hypertension (EHT)
Number of subjects: 124
Study: 11886767

Group type: EXPERIMENTAL
Intervention: Vitamin K(2) and D(3) combined therapy for 24 months
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Vitamin K(2) therapy alone for 24 months
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group receiving dietary therapy alone
Number of subjects: 172
Study: 10334534

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT), n = 39
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group (no hormones), n = 280
Number of subjects: 319
Study: 8547939

Group type: EXPERIMENTAL
Intervention: 8% glucose solution (CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo solution (PL)
Number of subjects: 9
Study: 2041284

Group type: EXPERIMENTAL
Intervention: Obsidan
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7030036

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 30841568

Group type: EXPERIMENTAL
Intervention: Red and processed meat intake
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Non-steroid anti-inflammatory drugs (NSAIDs) use
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Gene variant CCAT2 rs6983267
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Gene variant TP53 rs1042522
Number of subjects: 1038
Study: 27322597

Group type: EXPERIMENTAL
Intervention: Guarana 50 mg twice a day during chemoradiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25881590

Group type: EXPERIMENTAL
Intervention: Cimicifuga foetida extract (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Estradiol valerate and medroxyprogesterone acetate (Group B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Estradiol valerate and progesterone (Group C)
Number of subjects: 96
Study: 23551027

Group type: EXPERIMENTAL
Intervention: Gesture group (speech and gesture)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (only speech)
Number of subjects: 184
Study: 21716983

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate solution used twice daily for 3 months
Number of subjects: 127
Study: 19699918

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion at 4 cc/hour for 100 hours
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (normal saline solution) infusion
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion
Number of subjects: 124
Study: 30872289

Group type: EXPERIMENTAL
Intervention: NEWS2 (with delirium included)
Number of subjects: 71379
Study: 12921544

Group type: EXPERIMENTAL
Intervention: Midwives accompany laboring women throughout the birth process until two hours after delivery (n = 3,437)
Number of subjects: 6758

Group type: COMPARATOR
Intervention: Traditional management with intermittent midwife visits (n = 3,321)
Number of subjects: 6758
Study: 10848851

Group type: EXPERIMENTAL
Intervention: Elective surgical repair of abdominal aortic aneurysm
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Higher serum creatinine level
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Lower forced expiratory volume in 1 s (FEV1)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Age, serum creatinine level, and FEV1
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Younger patients with below average creatinine levels and above average FEV1
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Older patients with above average creatinine levels and below average FEV1
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Published clinical prediction rule
Number of subjects: 820
Study: 9356531

Group type: EXPERIMENTAL
Intervention: Carbohydrate deprivation for 24 hours (one-third of baseline carbohydrate intake)
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-fat food intake
Number of subjects: 7
Study: 9116627

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 3898670

Group type: EXPERIMENTAL
Intervention: Dipyridamole (8 mg for adults, 50 mg for schoolchildren, 24 mg for kindergarten children) administered orally every 8 days during the epidemic period (January-March 1983)
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1811
Study: 29743334

Group type: EXPERIMENTAL
Intervention: High water (HW) intake based on an individualised water intake prescription
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ad libitum (AW) water intake
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High water (HW) intake
Number of subjects: 50
Study: 26467700

Group type: EXPERIMENTAL
Intervention: Relamorelin, 100 μg, SQ
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo SQ
Number of subjects: 18
Study: 25241324

Group type: EXPERIMENTAL
Intervention: Best endovascular therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best open surgical treatment
Number of subjects: 0
Study: 21474566

Group type: EXPERIMENTAL
Intervention: Treatment group (upper canines)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Miniscrew group (miniscrew implants)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (upper second premolars)
Number of subjects: 16
Study: 19960205

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication combined with posterior gastropexy (group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without posterior gastropexy (group B)
Number of subjects: 82
Study: 18413295

Group type: EXPERIMENTAL
Intervention: Active CRT (CRT+)
Number of subjects: 23
Study: 16002776

Group type: EXPERIMENTAL
Intervention: Low amount, moderate intensity exercise (walking 12 miles/wk at 40‐55% of peak oxygen consumption)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Low amount, vigorous intensity exercise (jogging 12 miles/wk at 65‐80% of peak oxygen consumption)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: High amount, vigorous intensity exercise (jogging 20 miles/wk)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 175
Study: 12634266

Group type: EXPERIMENTAL
Intervention: tiapride/carbamazepine (A)
Number of subjects: 127

Group type: COMPARATOR
Intervention: clomethiazole (B)
Number of subjects: 127

Group type: COMPARATOR
Intervention: diazepam (C)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: tiapride/carbamazepine (D) in intoxicated patients
Number of subjects: 127